image 30.svg

image 26.svg

livemint logo.svg

image 29.svg

image 28.svg

image 31.svg

image 27.svg

Featured in

Urgent findings from head-CT scans prioritised by AI at NHS Greater Glasgow and Clyde to support winter A&E pressures

<a href="https://medica.co.uk/">Medica</a>&nbsp;is of the leading teleradiology providers in the UK and has been supporting clinical radiologists since 2004 to deliver the best patient care. Medica’s service is in use by over 100 NHS hospitals.

Learn more about how this collaboration has given radiologists the tools they need to conduct better analyses and report with greater confidence.

Fill the form for full case study

small_impact 4.webp

thumbnail_impact 4.webp

impact 4.webp

24/7 emergency teleradiology reporting of stroke and neurocritical concerns

The Qure.AI Impact Report for FY 22-23 highlights the company's use of AI in healthcare to enhance accessibility, affordability, and timeliness of care globally. It outlines various case studies, including their work in TB screening in Africa, lung cancer detection in Vietnam, and stroke care in the U.S. 

The report details partnerships, growth in AI deployment, regulatory achievements, and future goals, emphasizing their commitment to improving healthcare outcomes through AI innovation.

Complete the form to access the full report


large_Impact Report 22-23.webp

medium_Impact Report 22-23.webp

small_Impact Report 22-23.webp

thumbnail_Impact Report 22-23.webp

Impact Report 22-23.webp

Qure.AI FY 22-23 Impact Report: Global AI Healthcare Innovations

With a pioneering grant from the <a href="https://www.qure.ai/partners/ihf-partnership">India Health Fund (IHF)</a>,&nbsp;Qure.ai&nbsp;has set out to revolutionise TB diagnosis through its point-of-care, Smartphone-based Chest X-ray Tuberculosis Triage for Analog CXRs and a web-based solution for Digital CXR at Harriet Benson Memorial Hospital in Uttar Pradesh's Bundelkhand region. This initiative has empowered Qure to enable instant screening of analog chest X-ray films via smartphone photographs, marking a significant leap in diagnostic capabilities.

See how AI is aiding in detecting and managing tuberculosis (TB) effectively.

large_HB case study-02.webp

medium_HB case study-02.webp

small_HB case study-02.webp

thumbnail_HB case study-02.webp

HB case study-02.webp

Qure.ai & Harriet Benson: AI-Powered TB Care Transformation

AI presents a significant opportunity to enhance the use of Chest X-rays (CXRs), particularly for active case finding for tuberculosis. While adoption is growing, especially in developing nations, it's still in its early stages and heavily dependent on donor funding.

This proposed AI CXR Index aims to guide stakeholders in prioritising and promoting adoption tailored to each country's needs. Analysis reveals key drivers, including the extent of need, intent, and ability to roll out AI. Recommendations are provided for stakeholders to facilitate adoption and effectiveness.

Through comprehensive analysis, four key dimensions driving the use of AI for CXRs have been identified: the extent of need, level of awareness, intent, and interest, and the ability to roll out AI technology. These dimensions encompass various factors, such as the shortage of radiologists, awareness among decision-makers, infrastructure availability, and regulatory frameworks.

Countries were further categorised into five archetypes based on their scores, ranging from Frontrunners ready for scale to Skeptics with the ability but lacking intent. This classification facilitates tailored support from stakeholders to each group of countries.

Lastly, several recommendations have been articulated for key stakeholders, including AI and hardware companies, donors, multilaterals, and high TB-burden countries, aimed at fostering greater adoption and effectiveness of AI for CXRs.

Fill the form for full report

large_Alstonia Impact.webp

medium_Alstonia Impact.webp

small_Alstonia Impact.webp

thumbnail_Alstonia Impact.webp

Alstonia Impact.webp

AI Adoption for X-rays : A roadmap for future

Discover the groundbreaking strides in healthcare innovation in Lesotho, a collaborative effort led by Partners In Health (PIH), the Ministry of Health of Lesotho, and Qure.ai. This partnership exemplifies a commitment to combating tuberculosis (TB) and enhancing healthcare standards across the nation. With Lesotho facing a high disease burden amidst constrained resources, PIH has been at the forefront, implementing innovative solutions to these challenges.&nbsp;

Addressing the critical healthcare needs of Lesotho, PIH has initiated comprehensive programs focusing on the national diagnosis, treatment, and supportive care for multi-drug-resistant tuberculosis (MDR-TB). These initiatives are pivotal in transforming the landscape of TB care, ensuring access to essential services for the most vulnerable populations.&nbsp;

Qure.ai is pioneering advancements in TB detection with its cutting-edge qXR algorithm, which has become a cornerstone of community screening programs across seven key locations in Lesotho: Bobete, Nkau, Nohana, Tlhanyaku, Lebakeng, Mafeteng, and Qacha's Nek. This innovative technology facilitates early detection of TB, a critical step in curbing the spread of this deadly disease.&nbsp;

Since its implementation in July 2022, the qXR algorithm has processed over 6,000 scans, identifying approximately 1,100 individuals with potential TB cases for further confirmatory testing against the Gold Standard – GeneXpert. This significant achievement underscores the impact of leveraging technology in healthcare, offering hope for a TB-free future in Lesotho.&nbsp;

Explore this case study to gain insights into how strategic partnerships and technological innovation are reshaping healthcare in Lesotho, setting a precedent for global health initiatives aimed at eliminating tuberculosis and enhancing overall health outcomes.&nbsp;

For full case study

large_Lesotho.webp

medium_Lesotho.webp

small_Lesotho.webp

thumbnail_Lesotho.webp

Lesotho.webp

Transforming Healthcare in Lesotho with AI: A Case Study on Combating Tuberculosis 

Qure.ai has launched a five-point guide to steer UK NHS Trusts and Imaging Networks through the practicalities of activating Artificial Intelligence (AI).&nbsp;&nbsp;

‘Demystifying AI Deployments’ gives easy-to-follow steps to assist with the agile and efficient roll-out of diagnostic AI. It includes:

Answering key questions such as what comes first in AI deployment and who does what, the guide is a must for Radiology individuals and Imaging Departments planning for AI activation and deployment.&nbsp;&nbsp;

Fill out the form to access the guide

large_Five Point Guide .webp

medium_Five Point Guide .webp

small_Five Point Guide .webp

thumbnail_Five Point Guide .webp

Five Point Guide .webp

Qure.ai’s five-point guide to AI deployment in healthcare

This guide is dedicated to advancing lung health diagnostics through AI-enabled chest X-ray screening, bringing this innovative approach to the forefront of primary healthcare.

Chest X-rays, as recommended by the WHO, are a cornerstone in detecting common lower respiratory diseases such as pneumonia, TB, and COPD, particularly in primary care environments. Despite their widespread availability, the interpretation of these X-rays necessitates specialized radiologists, a resource that is markedly scarce in many global regions. This shortage not only impedes timely diagnosis but also escalates treatment costs and increases mortality risks.

Recognizing the critical need for skilled professionals, advanced diagnostic facilities, and the right technological tools, Qure's TB Reach Wave 11 initiative has been meticulously designed to simplify your decision-making process in selecting the most effective diagnostic tools. Our focus on artificial intelligence (AI) offers a pathway to assist clinicians in expediting diagnosis, thereby diminishing the duration and complexity of both investigation and treatment.

Explore the transformative potential of AI in enhancing your lung disease detection capabilities. We invite you to access our comprehensive support document and join us in this pivotal journey towards improved healthcare outcomes.

Fill out the form below for the full document:

large_TB Reach Wave 11 -01.webp

medium_TB Reach Wave 11 -01.webp

small_TB Reach Wave 11 -01.webp

thumbnail_TB Reach Wave 11 -01.webp

TB Reach Wave 11 -01.webp

Qure.ai: TB REACH Wave 11 Support Document

Qure.ai Technologies Limited is committed to achieving Net Zero Emissions by 2050

Baseline Emissions Footprint Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.&nbsp; BASELINE YEAR: H1 FY24 Qure.ai Technologies Limited is incorporated in the UK in 2021 and has not published carbon emissions for the years FY22 and FY23. Qure UK is a fully owned subsidiary of Qure.ai India. Qure India has started assessing carbon emissions from FY24 and have published our first Carbon&nbsp;

Reduction Plan for H1 FY24. Regarding scope 1 emissions, Qure.ai's services are directly delivered on AWS as a software. So, technically we have Zero scope 1 emissions at this point of time.&nbsp;

Baseline Year Emissions.webp

Carbon reduction overview.webp

Current Year Emissions Reporting (Same as baseline year emissions)

Reporting Year Emissions.webp

Qure.ai is a growing organisation and has been expanded rapidly in the last 5 years. We went from less than 30 employees and 10 deployments in 2017 to more than 300 employees and 1600+ sites across 80+ countries by 2023. This depicts the rate at which Qure is growing and we have been aggressively investing in human and technical resources. We can foresee Qure growing at this pace for the next 5 years and expecting a net positive carbon emissions.&nbsp;

However, Qure is committed to Net Zero carbon emissions and have started implementing multiple sustainable and eco-friendly initiatives across various business operations.&nbsp; Carbon Emission Projection: H1 FY29

Carbon emssio projection H1 FY29.webp

During the next 5 years we will introduce the following ESG initiatives:

Carbon reduction targets.webp

Activities which qure will take up: 1. Renewable-Powered Data Servers: Qure.ai is committed to sustainability by investing in data servers powered by renewable energy sources. This strategic choice significantly reduces our scope-2 carbon footprint.

2. Sustainable Procurements: We actively engage with vendors who share our mission of achieving carbon neutrality by 2050,ensuring that our supply chain aligns with our environmental goals.

3. Green Travel and Commute: We promote sustainability by encouraging electric and renewable energy sources for employee travel and commuting, thereby reducing our carbon emissions.

4. Solar-Powered Office: Qure.ai is taking steps to make one of its offices run entirely on solar energy, contributing to clean and green operations.

5. Eco-Friendly Technology: In our pursuit of environmental responsibility, we invest in eco-friendly technologies to power our computing infrastructure, making a positive impact on the environment.

6. Employee Engagement: To foster a culture of sustainability, we conduct training sessions to educate employees about the importance of environmental stewardship. We encourage employees to propose green initiatives and practices, making sustainability a part of our organizational DNA.

7. Carbon Offset Initiatives: In our commitment to carbon reduction, we invest in carbon offset projects, such as reforestation and renewable energy initiatives. We also explore partnership opportunities with environmental organizations and join carbon offset programs to contribute to a greener planet.

Establishing Our ESG Core Team

At Qure.ai, we consider sustainability to be more than a mere buzzword. It's a fundamental commitment that we are passionate about. To ensure that our dedication to Environmental, Social, and Governance (ESG) principles goes beyond empty rhetoric and transforms into impactful actions, we have established our ESG Core Team. The idea behind this team was to incorporate sustainability practices into our operational fabric, as envisioned by our leadership.&nbsp;

The ESG Core Team comprised of cross-functional experts from our executive leadership team pledges to reduce our carbon footprint, champion ethical and responsible business practices, and promote a culture of inclusivity and equity. This is the start of a journey toward a sustainable and equitable future, with the ESG Core Team leading the way and ensuring that every step we take embodies ESG values.&nbsp;

Currently, the key commitee members include:&nbsp;

1. Bhargava Reddy, Chief Operating Officer&nbsp;

2. Anushree Saha, General Counsel &amp; Company Secretary&nbsp;

3. Sonu Vijan, AVP, Travel &amp; Admin&nbsp;

4. Anurag Sharma, Manager, Legal Affairs and Strategy&nbsp;

5. Bunty Kundnani, Chief Regulatory Officer&nbsp;

6. Dhruv Shah, Director, Business Intelligence &amp; Operations&nbsp;

7. Divya Gupta, Chief Growth Officer&nbsp;

8. Poonam Ajgaonkar, Chief People Officer&nbsp;

9. Saniya Pawar, VP, Impact &amp; Evidence&nbsp;

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.&nbsp;

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard 13 and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.&nbsp;

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.&nbsp;

This Carbon Reduction Plan has been reviewed and signed off by&nbsp; Mr. Bhargava Reddy, Chief Operating Officer, Qure.

Screenshot 2023-10-26 at 1.38.35 AM.png

https://ghgprotocol.org/corporate-standard https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting https://ghgprotocol.org/standards/scope-3-standard&nbsp;

large_Carbon reduction title.webp

medium_Carbon reduction title.webp

small_Carbon reduction title.webp

thumbnail_Carbon reduction title.webp

Carbon reduction title.webp

Qure.ai's Carbon Reduction Plan

Early findings of a qXR AI study at Frimley Health NHS Foundation Trust have shown&nbsp;high accuracy&nbsp;in triaging chest X-rays as normal. Other highlights include:

Please fill out the form to access full case study and learn how to leverage AI for medical imaging efficiency gains.

large_Chest X-Ray reporting-01.webp

medium_Chest X-Ray reporting-01.webp

small_Chest X-Ray reporting-01.webp

thumbnail_Chest X-Ray reporting-01.webp

Chest X-Ray reporting-01.webp

AI Chest X-ray triage of normal / abnormal boosts radiology efficiency in NHS

LungIMPACT trial starts gathering real-world evidence with aim of saving lives now and into the future.

A collaborative study between UK academia, NHS hospitals and AI innovator Qure.ai has commenced to gather real-world evidence of AI-assisted diagnosis of lung cancer, which could help save thousands of lives.&nbsp;

The ‘LungIMPACT’ trial is using Qure’s qXR (CE Class IIb per EU MDR certified) solution to triage chest X-rays referred by GPs with the aim of identifying the presence of suspected lung abnormalities and give immediate reporting. This may then enable a patient to be referred for a same-day CT scan if lung cancer is suspected, speeding up access to a confirmed diagnosis and treatment planning.&nbsp;&nbsp;

The trial is now underway with Qure’s AI tool implemented at two NHS hospital Trusts, further NHS sites will also be deployed and ready to contribute to the study in a couple of months.&nbsp;

“Every year in the UK more than 35,500 people lose their lives due to lung cancer. We know that the speed of diagnosis is critical to achieve the best outcomes in lung cancer and to reduce stress and worry for patients. We have previously found that only a 15-day reduction in time to diagnosis increases survival by 200 days and immediate action on a chest X-ray that is suspicious for lung cancer reduces time to diagnosis by 30 days. AI may be a way to identify suspicious chest X-rays rapidly. Studies with AI are needed to evaluate the clinical value and impact to ensure safe and effective implementation,” states Professor David Baldwin, Chair of the UK Clinical Expert Group for Lung Cancer and Mesothelioma; National Clinical Lead for Lung Cancer, NHSE/I; Clinical Advisor to the UK National Screening Committee, Department of Health and Social Care; Respiratory Consultant at Nottingham University Hospitals NHS Trust; and Honorary Professor of Medicine at the University of Nottingham.&nbsp;&nbsp;

“We are delighted that the first hospital sites involved in the LungIMPACT trial are now live and the collaboration is gathering pace. The earlier cancer can be detected, the better chance patients have of survival. AI can be helpful in expediting diagnosis, and we hope that studies like this will gather the evidence needed to validate its role,” states Darren Stephens, Senior Vice President &amp; Commercial Head UK and Europe of Qure.ai.&nbsp;

The work was commissioned and funded by the NHS Cancer Programme, with the support of SBRI Healthcare and the NHS Accelerated Access Collaborative.&nbsp;&nbsp;

The NHS and academic teams have designed the study and all data will be analysed and reported independently from Qure.ai. Nottingham is leading the research on the back of the pioneering work on national rapid diagnostic pathways, AI imaging research and cancer screening.&nbsp;

It is led jointly by Professor David Baldwin, and Dr Nick Woznitza, a Consultant Radiographer at University College London Hospitals (UCLH) NHS Foundation Trust, and Clinical Academic at Canterbury Christ Church University. It also involves the expertise of Dr Richard Lee, National Institute for Health Research Specialty Lead Screening, Prevention and Early Detection, Dr Neal Navani, Senior Clinical Lead of the UK National Lung Cancer Audit.&nbsp;&nbsp;

Channel Partners:&nbsp;GE HealthCare, Magentus

large_web feature_lung cancer-01.webp

medium_web feature_lung cancer-01.webp

small_web feature_lung cancer-01.webp

thumbnail_web feature_lung cancer-01.webp

web feature_lung cancer-01.webp

Accelerating lung cancer diagnosis through LungIMPACT trial

In the heart of Maharashtra, India, a narrative of profound disparities unfolds. Mumbai, with its shimmering skyscrapers, stands as a testament to India's economic prowess, while a mere 390 kilometres away, Chinchpada's remote tribal expanse narrates a different story, marked by developmental challenges. Yet, in the shadow of their economic divide, both confront relentless health adversaries: the ubiquitous COVID-19 and the age-old threat of Tuberculosis (TB).&nbsp;

But a fresh chapter is being written in this story. And it is being driven by innovation and technology.&nbsp;&nbsp;

Leveraging the power of Artificial Intelligence (AI), a solution is at hand that transcends these disparities. Enter Qure.ai, with our innovative chest X-ray screening tool, qXR. Supported by the ambitious SAMRIDH Grant, an alliance between USAID and IPE Global, qXR promises to identify signs of TB within minutes. The solution’s efficacy shines equally in Mumbai's bustling clinics and Chinchpada's sparse healthcare facilities.&nbsp;

Clinicians on the ground, once burdened by an overwhelming patient load, are already testifying to its transformative potential. They are also more positive about being able to impact patient lives for the better. They affirm qXR's transformative prowess, highlighting its promise not just as a healthcare solution, but as a beacon of hope.&nbsp;

Mumbai and Chinchpada might be worlds apart, but Qure.ai's AI solution seamlessly integrates into their differing clinical settings, demonstrating the promise of technology as a great equalizer.&nbsp;

Witness a journey where health disparities are being challenged head-on, and the vision of achieving health equity through AI isn't just a dream—it's a rapidly emerging reality.&nbsp;&nbsp;

Want to dive deeper into this fascinating tale of technology combating healthcare inequities? Fill out the form &amp; download the full case study now!&nbsp;

large_Maharashtra case study coverpage thumbnail.webp

medium_Maharashtra case study coverpage thumbnail.webp

small_Maharashtra case study coverpage thumbnail.webp

thumbnail_Maharashtra case study coverpage thumbnail.webp

Maharashtra case study coverpage thumbnail.webp

A tale of two cities: AI for Health Equity

Tuberculosis rates have been high across Purnia, Bihar. Dr. Alexander Philip who has chosen to dedicate his medical skills to the district, needed as much support as possible to curb TB rates and treat patients effectively. Aided by the Samridh Grant,&nbsp;Qure.ai&nbsp;has deployed its AI solution at CMCH Purnia to help detect TB faster. Qure's qXR is helping address a skewed doctor-patient ratio and demonstrating that cutting-edge solutions can reform healthcare at the grassroots. Download the case study to know more:

In the heart of Eastern India, Bihar's Purnia District tells a story not of its landscapes but of human resilience against overwhelming healthcare adversities. With incomes hovering at a mere USD 5 per month, this region, emblematic of chronic impoverishment, has become the focus of nationwide change through the Aspirational Districts Programme (ADP). A grim reminder of healthcare's staggering disparities, Purnia's tale finds its light in the Christian Medical Centre and Hospital (CMCH), an oasis of hope in an otherwise parched land.&nbsp;

But as Tuberculosis (TB) and COVID-19 cast long shadows over this district, a new dawn emerges from an unexpected quarter—Artificial Intelligence.&nbsp;

In a groundbreaking collaboration, the SAMRIDH Grant aligns with Qure.ai, deploying qXR—an AI-powered chest X-ray screening tool—at CMCH. This potent alliance is more than just technology meets medicine; it's hope meeting reality. Within its early stages, over 2,500 X-rays were seamlessly processed, pinpointing 299 TB-presumptive patients—a feat of early detection that has tangible, life-saving ramifications.&nbsp;

Yet, the reach of this initiative goes beyond clinics and X-ray rooms. Deep into the heart of Purnia, in school compounds and community hubs, qXR is impacting lives, with events seeing children screened and communities educated about TB's insidious threat. With engaging skits and local dialect songs, the essence of medical innovation merges seamlessly with the tapestry of local culture, exemplifying the transformative power of community, technology, and collaboration.&nbsp;

Purnia's narrative, while specific in geography, reverberates with global significance. It's more than a testament to the marvels of AI in healthcare; it's a signal for what's possible even amidst the most daunting challenges.&nbsp;

Join us on a journey through Purnia's challenging terrains and witness how AI is not just transforming healthcare but rebuilding hope in the heartlands of Bihar. Dive into a story of innovation, resilience, and progress.&nbsp;

For a deeper exploration of this compelling narrative, fill out the form and download the full case study today.&nbsp;

large_PURNIA-CASE-STUDY-COVER-PAGE_THUMBNAIL_-01.webp

medium_PURNIA-CASE-STUDY-COVER-PAGE_THUMBNAIL_-01.webp

small_PURNIA-CASE-STUDY-COVER-PAGE_THUMBNAIL_-01.webp

thumbnail_PURNIA-CASE-STUDY-COVER-PAGE_THUMBNAIL_-01.webp

PURNIA-CASE-STUDY-COVER-PAGE_THUMBNAIL_-01.webp

AI helps overcome healthcare challenges in Bihar

AI toolkit to simplify the AI deployments for TB programs

Embracing the potential of AI can seem overwhelming at first, but with the right partner by your side, the journey becomes more manageable and enlightening. Introducing the<a href="https://qure.ai/">&nbsp;Qure.ai</a>&nbsp;AI Toolkit—a comprehensive solution designed to alleviate the challenges and demystify the process. Built upon industry-leading practices, our toolkit simplifies the intricate aspects of AI implementation, enabling you to unlock transformative insights for your program. Discover a world of possibilities with our AI Toolkit and embrace the power of artificial intelligence.

large_AI-toolkit-banner@2x.png

medium_AI-toolkit-banner@2x.png

small_AI-toolkit-banner@2x.png

thumbnail_AI-toolkit-banner@2x.png

AI-toolkit-banner@2x.png

Introducing AI Toolkit: Simplifying AI deployments for TB Programs

Presenting  The Global Fund  Application Support Package for AI-enabled CXR-based TB case finding. Created by Qure, this document highlights innovations in AI deployment models across different TB settings. Comprising our AI-powered integrated disease management workflow tool, we at Qure look forward to strengthening your TB elimination efforts and building Resilient and Sustainable Health Systems (RSSH). This comprehensive document will help overcome the digital divide gap to ensure equitable access to quality healthcare, especially in a low-resource setting.

Fill the details to download the document

large_impact 2.webp

medium_impact 2.webp

small_impact 2.webp

thumbnail_impact 2.webp

impact 2.webp

The Global Fund  Application Support Package for AI-enabled CXR-based TB case finding

<a href="https://blog.vrad.com/in-the-wild-mednax-and-qure.ai-partnership-guiding-ai-advancements">vRad</a>, a leading teleradiology provider in the U.S., has teamed up with Qure.ai to integrate AI-driven solutions in stroke care. This collaboration addresses the urgency required in treating over 795,000 stroke patients annually in the U.S., where each minute is crucial.

A stroke claims a life every 3.5 minutes, so an immediate medical response is crucial. The healthcare industry grapples with challenges such as limited capacity and increased demand for imaging, making quick and accurate decisions imperative.

Qure.ai's AI tool, <a href="https://www.qure.ai/product/qer">qER</a>, seamlessly integrates into vRad's workflows. Certified by FDA 510(k) and CE Class IIb, the tool interprets head CT scans, allowing for expedited and confident clinical decisions.

In a recent case at a rural Iowa medical center, a 68-year-old female was diagnosed and treated promptly due to AI prioritization, significantly improving her condition.

The vRad and Qure.ai partnership exemplifies how AI can revolutionize time-sensitive and critical healthcare sectors like stroke care. For more in-depth insights and metrics, download the complete case study.

large_impact 3.webp

medium_impact 3.webp

small_impact 3.webp

thumbnail_impact 3.webp

impact 3.webp

Elevating Radiology Care with Qure.ai & vRAD

No country aspires to be known for a high tuberculosis infection rate. But, unfortunately, Nigeria’s tuberculosis numbers are soaring rapidly, ranking third in the world, only behind India and China. Annually, the West African nation sees 590,000 new tuberculosis cases, and 245,000 Nigerians die of the disease every year.&nbsp;&nbsp;&nbsp;

From Insight to Impact: Our Case Studies